The Latest Cardiac and Vascular News
PALM SPRINGS, Calif., Aug. 24, 2026 /PRNewswire/ — The VIVA Foundation will spotlight the latest advances in vascular medicine as 26 clinical trials are presented during The VEINS and VIVA 2026, taking place October 3-6 at Bellagio Las Vegas. The highly anticipated late-breaking…
Appointments Support Accelerated Trial Enrollment, Market Development, Scalability, and Future CommercializationMOUNTAIN VIEW, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) — R3 Vascular Inc., a medical device company dedicated to developing and providing novel, best-in-class bioresorbable scaffolds for treating peripheral arterial disease (PAD), is pleased to announce the appointment of two senior executives as it accelerates trial enrollment, market development, scalability, and future commercialization. Robert Spanos has been appointed as Vice President, Global Market Development and Katie Segreto has been appointed as Vice President, Finance and Corporate Controller. Commenting on the appointments, Christopher M. Owens, President and CEO of R3 Vascular said, “On behalf of the R3 management team, I am very pleased to welcome Bob Spanos and Katie Segreto. Both bring exceptional expertise and proven leadership that will be instrumental as we advance the clinical development of MAGNITUDE®, accelerate our market presence, and build the infrastructure needed to support future commercialization. Bob’s deep experience in peripheral vascular markets and successful product launches will strengthen our commercial strategy and market expansion efforts, while Katie’s extensive finance leadership experience will help us scale our organization and position R3 Vascular for long-term growth. We are excited to have them join our team at this important stage for the company, including the recent rapid acceleration of our ELITE Clinical Trial enrollment, finalizing the advances in scaffold product line extensions, driving elite margin structure and setting the foundation throughout the organization to prepare for commercialization.” Robert Spanos is a seasoned cardiovascular medical device executive with more than 20 years of experience leading commercial strategy, clinical execution, and successful product launches across the endovascular and peripheral vascular markets. Throughout his career, he has built and led high-performance sales organizations while driving market adoption and revenue growth for innovative, first-to-market technologies. Prior to joining R3 Vascular, Robert held senior leadership roles including Executive Vice President of Corporate Operations for Emblok Inc., Vice President of Commercial Development at AngioDynamics, and Vice President of U.S. Sales Accounts at Eximo Medical, where he played a critical role in IDE trials, FDA 510(k) submissions, global commercial launches, and acquisition integrations. He has also served in key leadership positions at IDev Technologies, Mercator MedSystems, FoxHollow Technologies, and Guidant Endovascular Solutions, contributing to multiple successful product launches and strategic exits. He holds a Bachelor of Business Administration in Marketing from the University of St. Thomas. Robert Spanos said, “I’m excited to join the R3 Vascular team and contribute to the advancement of MAGNITUDE, a remarkable next-generational bioresorbable platform. Its ultra-high molecular weight polymer delivers strength and flexibility needed to address the unique demands of tibial vessels in patients with critical limb ischemia (CLTI), while offering potential applications in other vascular beds, including the superficial femoral and coronary arteries. I look forward to helping drive the successful execution of the company’s clinical, regulatory and commercial objectives.” Katie Segreto brings more than 18 years of finance leadership experience building and scaling high-performing finance organizations across the medical device, biotechnology, and technology sectors. She has guided both public and private companies through periods of substantial growth and transformation. Prior to joining R3 Vascular, Katie served as Vice President of Finance for Kronos Bio, a publicly traded clinical-stage biotechnology company, where she led the finance organization through the company’s post-IPO expansion. Previously, Katie served as Vice President of Finance at K Health, a venture-backed health technology company, where she built the finance function from the ground up, enabling the company’s growth from $0 to $20M in sales and through its Series C and D financings. Earlier in her career, Katie held finance leadership roles at Bonobos, a high-growth ecommerce company acquired by Walmart, and spent eight years in the Life Science audit practice at PwC, advising biotech and med tech companies on audit and accounting strategy. Katie holds a Bachelor of Arts in Business Management Economics from the University of California, Santa Cruz and is a Certified Public Accountant (inactive). Katie Segreto added, “I am thrilled to join the R3 Vascular team at such an important point in the company’s growth and to help advance this innovative bioresorbable technology. The platform’s potential to address important unmet needs and improve outcomes in vascular care is particularly compelling. I look forward to supporting the advancement of the company’s clinical and commercial objectives to ultimately bring this technology to the patients who need it most.” About R3 Vascular Inc.R3 Vascular is a privately-held medical device company that develops a novel technology platform for the next generation of fully bioresorbable drug eluting sirolimus coated vascular scaffolds. These are designed to deliver the ‘stent-like’ support of a scaffold along with the anti-inflammatory and anti-proliferative result of sirolimus, but ‘disappearing’ over time as the vessel heals. R3 Vascular is headquartered in Mountain View, California. More information can be found at www.r3vascular.com. Media Contact:David Gutierrez, Dresner Corporate Services, (312) 780-7204, dgutierrez@dresnerco.com
MENLO PARK, Calif., Aug. 20, 2026 /PRNewswire/ — Subtle Medical, a leading provider of AI-powered medical imaging solutions, today announced the appointment of Lawrence N. Tanenbaum, MD, FACR, as Executive Medical Director and Chair of the company’s Medical Advisory Board. A nationally…
WASHINGTON, Aug. 20, 2026 /PRNewswire/ — The Heart Failure Society of America (HFSA) announced the slate of 2026 HFSA Award recipients who will be recognized at the HFSA Annual Scientific Meeting 2026, October 9-12 in Phoenix, AZ. Our field advances because of the dedication,…
Peer-reviewed research in JACC Advances reveals patient-initiated, symptom-triggered 6-lead ECG monitoring nearly doubles the diagnostic yield of conventional continuous monitoring modalitiesMOUNTAIN VIEW, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) — AliveCor, the global leader in AI-powered cardiology, today announced a new prospective cohort study (the M-KEEPS study) conducted by researchers at the University of Rochester Clinical Cardiovascular Research Center and published in JACC Advances. The study, titled “Symptom-Triggered 6-Lead ECG Monitoring Significantly Increases Arrhythmia Detection Beyond Traditional Ambulatory Monitoring,” establishes that 30-day use of the handheld KardiaMobile 6L (KM6L) device outperforms traditional short-duration ambulatory ECG monitoring alone in detecting clinically significant arrhythmias. By empowering patients to capture medical-grade recordings on-demand during symptomatic episodes, the KM6L device achieved an overall diagnostic yield nearly double that of standard clinical monitoring modalities. Key Clinical Findings & Diagnostic YieldThe study evaluated 350 adult patients presenting with unexplained palpitations, dizziness, or lightheadedness who were concurrently tracked using both a physician-ordered standard ambulatory monitor (24/48-hour Holter or an extended patch ECG monitor) and a KM6L device for 30 days. Doubling the Diagnostic Capture: Clinically significant arrhythmias were detected in 66 patients (18.9%) overall across both monitoring types. Traditional ambulatory monitors identified arrhythmias in only 27 patients (7.7%), whereas the KM6L device detected arrhythmias in 52 patients (14.9%) (P < 0.001). Exclusive Arrhythmia Detection: A total of 39 arrhythmia episodes (11.1%) were captured exclusively by the KM6L device and completely missed by conventional continuous monitoring options (p = 0.0008). Outperforming Prolonged Patch Monitors: In an exploratory analysis of patients wearing extended patch ECG monitors for 7 days or longer, the patch devices documented arrhythmias in 9.8% of patients (9 out of 93), while the KM6L device detected arrhythmias in 23.9% of those same patients (22 out of 93) (p 130 bpm)0202Pause1001Total13391466 Redefining the Standard of Care”The M-KEEPS study showed that the KardiaMobile 6L hand-held device enabled patient-initiated ECG recordings with 88% of participants—across a broad range of ages and with two-thirds being women—evaluating the device as easy to use,” said Wojciech Zareba, MD, PhD, of the Clinical Cardiovascular Research Center at the University of Rochester. “Symptom-triggered ECG recordings obtained over 30 days were superior to standard 24- or 48-hour Holter recordings and to prolonged multiday recordings in detecting clinically significant arrhythmias. KM6L might be considered as the first line of diagnostic process in individuals with uncertain causes of cardiac symptoms.” The research team also highlighted how real-world clinical paradigms are shifting toward patient-activated technology to address these exact workflow bottlenecks. “Traditional short-duration monitoring simply misses too many transient events, creating a costly diagnostic blind spot for clinicians,” said Dr. Dave Albert, Chief Medical Officer and Co-founder of AliveCor. “This landmark study from the University of Rochester proves that putting our medical-grade, 6-lead device directly into patients’ hands nearly doubles the diagnostic yield. By empowering patients to capture arrhythmias the moment symptoms occur, we can accelerate accurate diagnoses, optimize clinical workflows, and get patients to life-saving treatment faster—ultimately preventing critical cardiac episodes and the compounding costs of undetected conditions.” High Data Quality and Exceptional Patient UsabilityA critical element of deploying consumer-facing medical technology is patient adherence and signal reliability. Across 6,251 total KM6L recordings collected during the study, 92.3% of the total recordings were deemed clinically interpretable by research technicians. In direct head-to-head temporal alignments, 88.3% of KM6L recordings were classified as top-tier, readable ECGs compared to 86.7% of traditional Holter recordings. Patient survey results at the end of the 30-day testing period indicated massive compliance and clinical satisfaction across a diverse demographic, where two-thirds of study participants were female: 88% of surveyed participants strongly agreed that the KM6L smartphone application was easy to use. 70% strongly agreed that obtaining a 6-lead ECG recording utilizing the left leg electrode was easy to complete. 88% strongly agreed that they felt more confident using the device to actively document their heart rhythms. In practice, the KM6L device functions seamlessly as an adjunct early in the cardiac diagnostic pathway. By reducing repeated short-term monitoring loops, the technology speeds up symptom-rhythm correlation, easing patient anxiety and minimizing unnecessary healthcare expenditures associated with an extended diagnostic search. AliveCor remains deeply committed to anchoring its innovations in rigorous clinical evidence, a dedication backed by more than 250 peer-reviewed articles. The company’s extensive research library, ranging from validation studies in JAMA to landmark trials in The Lancet, consistently proves that its medical-grade AI and hardware improve arrhythmia detection, streamline clinical workflows, and optimize patient outcomes. By continually subjecting its technology to independent scientific scrutiny, AliveCor provides physicians and patients with unmatched, data-driven confidence in remote cardiac care. For clinicians looking for more information on how to integrate Kardia devices into their workflow, visit: https://alivecor.com/health-systems. About AliveCorAliveCor, Inc., the leading provider of FDA-cleared personal electrocardiogram (ECG) devices, is transforming cardiology with its medical-grade AI solutions. The company was named to the inaugural TIME World’s Top Health Tech Companies 2025 list – recognition of its commitment to delivering innovative devices and services that empower patients and physicians with personalized, actionable heart data. With over 350 million ECGs recorded, the company’s Kardia devices are the most clinically validated personal ECGs in the world and can remotely detect six of the most common heart arrhythmias in just 30 seconds. The company’s latest offering, Kardia 12L ECG System, powered by KAI 12L cleared to detect 39 cardiac conditions (with determination availability varying by geography), was designed exclusively for use by healthcare providers. AliveCor’s enterprise platform allows third-party providers to manage their patients’ and customers’ heart conditions simply using state-of-the-art tools that provide easy front-end and back-end integration to AliveCor technologies, addressing gaps in care and improving the treatment experience for patients across a range of disease areas. AliveCor is a privately held company headquartered in Mountain View, Calif. For more information, visit alivecor.com and follow us on LinkedIn, X, Instagram and Facebook. Media ContactMorgan MathisDirector of Corporate Communications, AliveCorpress@alivecor.com
Registrations cover the BD-GT Microwave Ablation System and T-1610 Disposable Microwave Ablation NeedleNEW YORK, Aug. 20, 2026 (GLOBE NEWSWIRE) — Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) (“Baird Medical” or the “Company”), announced that the BD-GT Microwave Ablation System and T-1610 Disposable Microwave Ablation Needle have received product registrations from the Drug Regulatory Authority of Pakistan (“DRAP”), further supporting the Company’s commercial activities in the country. The registrations build on Baird Medical’s existing presence in Pakistan, where the Company announced regulatory approvals and initial commercial availability at the Armed Forces Institute of Radiology & Imaging (“AFIRI”) in January 2026. The latest registrations further expand the regulatory foundation supporting the availability and use of Baird Medical’s microwave ablation technology in the market. MWA is increasingly being utilized as a minimally invasive treatment approach for benign and malignant soft tissue tumors, offering physicians the ability to precisely ablate targeted tissue while potentially reducing the burden associated with more invasive surgical procedures. As awareness and adoption of image-guided ablation continue to develop in the United States and internationally, Baird Medical is focused on expanding the regulatory, commercial and clinical infrastructure supporting broader physician and patient access to its technology. “Building a meaningful global presence requires more than entering new markets. Establishing the infrastructure to support sustained clinical adoption of our technologies is critical to our long-term success,” said Haimei Wu, Chairwoman and CEO of Baird Medical. “Our progress in Pakistan reflects the broader global strategy we are executing at Baird Medical: expanding access to our technology, supporting physicians as they incorporate MWA into clinical practice, and building a commercial presence across markets where we see meaningful opportunities for long-term adoption. Furthermore, it provides expanded access to patients who are searching for an effective and minimally invasive solution for the treatment of their tumor. As we continue to build our global presence, our objective is to establish Baird Medical as a leading platform for minimally invasive ablation.” The registrations represent continued progress in Baird Medical’s international expansion strategy as the Company advances regulatory and commercial development of its minimally invasive ablation technologies across key global markets. The Company has established a commercial footprint, while continuing to further establish its presence in the United States. Earlier this year, physicians in Vietnam and Argentina successfully completed their first microwave ablation procedures using Baird Medical’s technology, demonstrating the progression from market entry to clinical utilization. The additional registrations in Pakistan further support this momentum as Baird Medical works to broaden physician and patient access to MWA technology across global markets. About Baird Medical Baird Medical is a global, pioneering medical device company specializing in minimally invasive ablation technologies for a range of solid tumors. The Company’s lead product, a microwave ablation (MWA) system, is FDA-cleared for soft tissue ablation and is being launched in the U.S. primarily for the treatment of benign thyroid nodules. In addition, the Company is expanding its minimally invasive technology portfolio, including IRE-based products and an AI-powered robotic ablation system. Baird Medical’s MWA solutions have been adopted by a growing number of leading U.S. institutions and private practice groups, including the Mayo Clinic, Columbia University Medical Center, and The George Washington University Hospital. The company is rapidly expanding its global commercial footprint, with sales now reaching markets across multiple continents. Forward-Looking Statements This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical’s future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as “may”, “could”, “should”, “expect”, “intend”, “might”, “will”, “estimate”, “anticipate”, “believe”, “budget”, “forecast”, “intend”, “plan”, “potential”, “predict”, or “continue”, or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements. Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (6) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled “Risk Factors” therein, and in ExcelFin’s other filings with the SEC. The foregoing list of factors is not exclusive. Additional information concerning certain of these, and other risk factors is contained in ExcelFin’s most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein, or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Contact: Lee RothBurns McClellan for Baird MedicalLroth@burnsmc.com
— Novel coils from Embolization, Inc., demonstrate consistent performance across a range of cases — BOULDER, Colo., Aug. 20, 2026 /PRNewswire/ — The novel, radiopaque, polymer-based embolic coil from Embolization, Inc., has now topped 125 implants nationwide, demonstrating continued…
SOUTH JORDAN, Utah, Aug. 19, 2026 (GLOBE NEWSWIRE) — Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer of healthcare technology, today announced that Sheri Lewis has agreed to join Merit as Executive Vice President of Global Operations, effective August 31, 2026. Ms. Lewis brings three decades of experience across global operations, manufacturing, and supply chain management. She previously held senior roles at SkinHealth Systems, Inc., Avantor, Medtronic, and Honeywell, leading global manufacturing, distribution, logistics, supply chain, quality, regulatory, environmental health and safety, and operational excellence functions across large, complex organizations. “Sheri is an accomplished operations executive with a strong record of leading complex organizations and building high-performing teams,” said Martha G. Aronson, Merit’s President and Chief Executive Officer. “Her experience strengthening integrated business processes, ensuring product availability, and driving global operational excellence will be important as Merit continues to scale globally and execute its long-term growth strategy.” To support continuity, Mr. Peterson will move into the role of Senior Advisor, where he will help ensure a smooth transition through March 5, 2027. At that time, Mr. Peterson will complete his service to Merit after more than 32 years with the company. Mr. Peterson has held leadership roles across Merit’s operations and engineering functions, most recently serving as Chief Operating Officer for the past four years. Throughout his career, he has strengthened product quality, improved on-time delivery, advanced operational efficiencies, and driven cost reductions. He also helped navigate supply chain constraints, raw material shortages, and the operational challenges of the COVID-19 pandemic. Mr. Peterson has consistently shown a deep commitment to supporting employees and their well-being. “Neil has been a dedicated and respected leader at Merit. His operational discipline, commitment to execution, and deep knowledge of our manufacturing and supply chain network have contributed meaningfully to the company’s growth and performance,” added Aronson. “We are grateful for his many contributions and for the important role he has played in strengthening our global operations.” ABOUT MERIT MEDICAL Founded in 1987, Merit is engaged in the development, manufacture, and distribution of proprietary medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves customers worldwide with a domestic and international sales force and clinical support team totaling more than 800 individuals. Merit employs approximately 7,500 people worldwide. CONTACTSPR/Media Inquiries Sarah Comstock Merit Medical +1-801-432-2864 | sarah.comstock@merit.com Investor Inquiries Mike Piccinino, CFA, IRC ICR Healthcare +1-443-213-0509 | mike.piccinino@icrhealthcare.com
PHOENIX, Aug. 19, 2026 /PRNewswire/ — Phoenix Children’s today announced the appointment of Carolina V. Guimaraes, MD, as Vice President and Chief of Radiology. “Every day, our clinical teams rely on Radiology to help answer critical questions and guide some of the most important…
NEWPORT BEACH, Calif., Aug. 19, 2026 /PRNewswire/ — Renata Medical, a privately held medical technology company dedicated to transforming care for children with congenital heart disease (CHD), today announced the close of a $25 million Series D financing round. The round was led by…
